FDA Fast Tracks UV1 Vaccine Combo for Mesothelioma
The U.S. Food and Drug Administration granted fast-track designation to a new therapeutic cancer vaccine. The approval is for UV1 in combination with the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) to manage malignant pleural mesothelioma that can’t be managed with surgery.
Therapeutic cancer vaccines, unlike preventive vaccines, treat existing cancers. Fast Track expedites the development of drug reviews for severe conditions. This way, the FDA can bring essential new drugs to patients earlier. With this designation, UV1 drug-maker Ultimovacs ASA will interact more frequently with the FDA dur...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Early Detection Tests for Mesothelioma Are in Development
Scientists in Australia are developing early detection tests for mesothelioma. The Asbestos and Dust Diseases Research Institute’s new test could potentially save lives. According to ADDRI’s academic and research director Dr. Anthony Linton, the tests will be similar to PCR tests already in use to detect COVID-19.
These new tests can find small amounts of DNA that cause disease. The PCR method, used since the 1980s, allows DNA samples to be studied in a higher level of detail. PCR is the tech behind the beginning of the 1990 Human Genome Project to identify and map human DNA.
“We have identified a...
Source: Asbestos and Mesothelioma News - February 13, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos Exposure Clinical Trials/Research/Emerging Treatments Doctors/Specialists Mesothelioma Source Type: news
U.S. Nuclear Missile Bases Under Investigation for Cancer Risks
The U.S. Air Force is investigating nuclear missile bases for asbestos and other potentially cancer-causing materials. The Associated Press recently revealed that the issues date as far back as the late 1980s. Reports prove that the Air Force has been aware of toxic chemicals at nuclear launch silos for decades.
Air Force documents reveal details about several leaks and spills at missile bases across the country over the course of several years. Records describe repeated spills or leaks affecting service members working at the sites. The documents reveal internal reports of asbestos leaks at missile silos in 1989, as ...
Source: Asbestos and Mesothelioma News - February 9, 2024 Category: Environmental Health Authors: Amy Edel Tags: Air Force Asbestos (general) Asbestos Exposure Cancer (Non-Meso) Source Type: news
Nonprofit Teams With Firefighter Union for Asbestos Ban Campaign
The Asbestos Disease Awareness Organization is teaming with the International Association of Fire Fighters on a new anti-asbestos campaign. In a continued push toward a national ban of the toxic mineral, the organizations have created a 120 foot high and 84 foot wide billboard in New York City’s Times Square.
A firefighter in full gear is the focal point of the advertisement. Written on the picture are the words: “Firefighters Face Risk.” Under that in large red letters it reads: “Ban Asbestos Now.”
The message is expected to make 1.5 million impressions a day and will be seen 4 times every hour for 1...
Source: Asbestos and Mesothelioma News - February 6, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos (general) Asbestos Exposure Awareness/Advocacy Mesothelioma Support/Support Groups/Organizations Source Type: news
Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Survival Gains
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Phase I Trial Improves Mesothelioma Survival More Than 200%
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
$30M Mesothelioma Verdict Awarded in Case Against Bridgestone
An Illinois jury has awarded $30 million in a mesothelioma case against tiremaker Bridgestone Firestone. Thomas Jackson was exposed to asbestos inadvertently brought home from his father’s job at one of the company’s tire manufacturing plants. Jackson died just five weeks after his mesothelioma diagnosis at 64 years old.
Attorneys for Jackson’s wife, Dorothy Jackson, successfully linked his peritoneal mesothelioma to asbestos fibers on his father’s work clothes. Nearly 100 pieces of evidence were used in the nine day trial tying Jackson’s secondary asbestos exposure to his father’s job, which began in 1965.
...
Source: Asbestos and Mesothelioma News - January 29, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos (general) Asbestos Exposure Companies Legal Mesothelioma Secondary Exposure talc Talcum Powder Verdict Source Type: news
Mounting Asbestos Lawsuits Forces Kelly-Moore Paints to Close
After nearly 80 years in business Kelly-Moore Paints is closing all stores nationwide. Kelly-Moore decided to shut down after spending a total of $600 million on asbestos settlements, while still dealing with cases being filed. The lawsuits stem from asbestos used in cement and texture products that the company had eliminated decades ago.
Kelly-Moore has furloughed around 700 employees due to the closures. The shutdown affects 157 retail locations and facilities in California, Nevada, Oklahoma and Texas.
The company plans on fulfilling all orders that customers have already placed through its Union City, ...
Source: Asbestos and Mesothelioma News - January 25, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos (general) Asbestos Exposure Companies Source Type: news
J & J to Pay $700 Million to Settle Talc Baby Powder Investigation
Johnson & Johnson’s $700 million deal will resolve a talcum powder investigation a group of 43 State Attorneys Generals launched. J&J is accused of not warning people about potential health risks linked to its talc-based baby powder.
This latest settlement won’t resolve thousands of other lawsuits that claim the company’s talc-based products cause cancer. In total 50,000 claims have been filed against J&J, the majority of which claim the company’s talc caused ovarian cancer. J&J maintains that its products don’t cause cancer.
“I view this settlement as part of J&J’s overall str...
Source: Asbestos and Mesothelioma News - January 24, 2024 Category: Environmental Health Authors: Daniel Mojica Tags: Asbestos (general) Asbestos Exposure johnson Litigation Mesothelioma Settlement Source Type: news
Study: Fibers Released from Asbestos Cement Far Exceed Limits
The installation and removal of asbestos cement products may put workers at significant health risks, according to a recent study published in the Annals of Work Exposures and Health. The nonprofit organization Occupational Knowledge International found that exposure levels to airborne asbestos exceed the short-term limit created by the Occupational Safety and Health Administration.
Exposure while cutting asbestos cement pipes can be more than 50 times higher than OSHA’s limit. The same study found that working with asbestos boards and corrugated roofing materials led to exposure levels about 24 times over t...
Source: Asbestos and Mesothelioma News - January 23, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos (general) Asbestos Exposure Asbestosis Lung Cancer (Non-Meso) Mesothelioma Source Type: news
Hess to Pay Up to $187 Million to Settle Asbestos Injury Claims
The global energy company Hess Corporation will pay up to $187 million to settle asbestos injury claims made in connection to an oil refinery that had been operating in the U.S. Virgin Islands. The claims cover those who worked at the refinery, their family and residents in the area who may have been exposed to asbestos and developed asbestos-related diseases such as mesothelioma.
According to a notice of settlement filed in Texas bankruptcy court, Hess and a non-operating subsidiary of Hess known as Honx, Inc., will pay $105 million. The funds will create an asbestos trust to cover more than 900 exposure-related ...
Source: Asbestos and Mesothelioma News - January 9, 2024 Category: Environmental Health Authors: Amy Edel Tags: Asbestos (general) Asbestos Exposure Companies Legal Source Type: news
Partial Building Collapse Possibly Spread Toxic Asbestos Dust
A 7-story apartment building partially collapsed in the Bronx, leaving behind a 12-foot high pile of debris on the street. An entire corner of the building came crashing down without warning, sending people on the sidewalk running as a cloud of dust engulfed the area. Given the age of the building, it’s likely that the building contained asbestos, which could have spread in the dust cloud.
Firefighters dug through the huge pile of debris for several hours looking for possible victims. No one was found, two people received minor injuries and 136 people were displaced.
“Unfortunately with situations like this...
Source: Asbestos and Mesothelioma News - December 18, 2023 Category: Environmental Health Authors: Amy Edel Tags: Asbestos (general) Asbestos Exposure Source Type: news
CARD Clinic to Release New Asbestos Research in 2024
The Center for Asbestos Related Disease has begun work on a series of new research articles scheduled to be released throughout 2024. The content will center around new studies concerning asbestos and autoimmune disease.
The articles will reveal details discovered in analyzing the health impact of people exposed to amphibole asbestos from Libby, Montana. This type of asbestos found in the former mining town takes less exposure to cause cancer than other types of the mineral such as chrysotile asbestos, which makes amphibole even more dangerous.
CARD’s first article is expected to be released in January 2024. ...
Source: Asbestos and Mesothelioma News - December 15, 2023 Category: Environmental Health Authors: Amy Edel Tags: Asbestos (general) Asbestos Exposure Clinical Trials/Research/Emerging Treatments Source Type: news
Polaris Submits Application for New Mesothelioma Treatment
Multinational biopharmaceutical company Polaris Group announced their application for a rolling submission of a new mesothelioma treatment this month. The Biologic License Application for the experimental drug ADI-PEG 20 is the first step in U.S. Food and Drug Administration approval.
The application outlines the use of ADI-PEG 20 for non-epithelioid mesothelioma alongside treatment with pemetrexed and platinum chemotherapy. Non-epithelioid subtypes include sarcomatoid and biphasic cell types, historically the most resistant to treatment.
Polaris stated in a press release, “Polaris Group’s development...
Source: Asbestos and Mesothelioma News - December 14, 2023 Category: Environmental Health Authors: Amy Edel Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
